Member Info for miavoce

Interesting comment from LD regarding the fact that they had considered stopping the vaccine work several times but had decided to progress due to the strength of their platform in generating T Cell responses as well as antibody.

LD doesn't believe that mRNA platforms needing 6 monthly boosters are the way forward, hence her comment on potentially doing a partnership deal on the DNA platform...

Interesting comment LD made when talking about whether they would partner on Covidity....she said maybe partner on Covidity or on the DNA vaccine platform ....clearly she believes that the world needs a DNA vaccine platform that works i.e. Immunobody...

I got the feeling that a commercial partnership in the mAb space may not be too far away...

Good to hear that there have been no toxicity issues with SCOV. Reason for the recent advert for trial participants is that they had to start slowly (dose one person and then wait a few days before dosing the next) but now that toxicity is OK they can accelerate. Things are where they should be (according to LD).

BionTech was a surprise, we've never heard that before as far as I recall

Lets hope the presentation is posted to their website (as is the case for all previous AGM presentations).

Thanks bobbust,

when you say 'Biontech want results from trial before committing' which trial are you referring to ?

Hi BOJO2020

do you believe that the FDA will be rigorously testing Parsortix i.e. running blood samples through it and analysing results ? KI though that the testing was done before the FDA submission and the results of the testing were included in the submission to the FDA.

The exact phrase used in the presentation was:
'FDA regulatory response anticipated in H2 2021'.

This was caveated with the usual footnote:
'ANGLE is following a De Novo FDA process for the Parsortix system as there is no predicate device. Consequently there is inherent uncertainty over the timing of the process and its ultimate success'

...nice.

Wiggle it, just a little bit...

Hi Boonco - not only did AGL fall on the same day as the POLX news but the AGL price fell sharply very soon after the POLX RNS was released in the afternoon - more then a mere coincidence I suspect....

Drums, as noted by researcher1 this de novo submission relates purely to getting approval for the capture and harvest of CTC's from the blood of patients with Metastatic Breast Cancer.

Angle will need to obtain separate approvals for other cancer types however this will be more straightforward than the de novo submission for several reasons:-

a) a lot of the technical aspects (ie related to the behaviour of the device rather than related to the specific cancer) won't need to be repeated - the submissions for further cancer types will only need to focus on demonstrating the capability to capture and harvest the CTC's

b) the initial approval will act as a predicate for subsequent submissions and therefore the 510k route can be followed rather than the de novo route which should simplify the approval process

c) the whole process of preparing for and obtaining approval will be a lot cheaper and hopefully a lot quicker

d) submissions for multiple cancer types could be done in parallel

Hi AquaeSulis01

these Reach RNS's will make no difference to the FDA approval as they are not part of the evidence set submitted by Angle to the FDA to demonstrate the capability to capture and harvest CTC's from the blood of patients with metastatic breast cancer (this is the what the FDA will be approving)

I think the market is becoming immune to these research related RNS's which point towards potential future revenue rather than immediate revenue (although in the case of the PD-L1 RNS revenue may come fairly quickly via our lab service). Still, each of these RNS's adds to the shaping of the medium / long term revenue picture which in turn would support a high take out price were Angle to be taken over by one of the majors.

Thanks C7. No, I had no reason for thinking they were buys, just interested in how you knew they were sells.

How do you know they were sells C7 ?

Your faith and perseverance will surely be rewarded hickorydickorydoc. How are the mice these days ?

Hi hickorydicorydoc

on the 16th of April, when the closing price was 98p, you posted that you were in a 'large plus position' and that you 'don't top slice or cut and run' and that you were 'here for the end game', and exhorted us to 'Keep the faith'. Your original post is copied below for your reference. Given that you must now be in substantially more profit than your were then (having not top sliced or cut and run), and that you are here for the end game, why the recent spew of posts attacking the company and its management - seems a very strange strategy for a committed holder such as yourself ?

Hi
I’m still here and Will be to the bitter or fruitful end am currently in large plus position but this has happened on many occasions over many years as my good friend Miss BMW will testify
I don’t top slice or cut and run I’m here for the end game
Keep the faith and keep safe
Good luck all